In summary, our data showed that SOX9 participated in DNA damage repair by promoting the expression and nuclear entry of MMS22L upon oxaliplatin treatment, which induced oxaliplatin resistance in CRC cells. This evidence concerns the gene SOX9 and colorectal carcinoma.